Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information

v3.24.1.1.u2
Balance Sheet Information
 3 Months Ended
Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Information Balance Sheet Information
Cash, Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
March 31, 2024 December 31, 2023
Cash and Cash Equivalents $ 31,276,330  $ 2,454,684 
Restricted Cash, Non-current 4,084  4,267 
Total Cash, Cash Equivalents and Restricted Cash $ 31,280,414  $ 2,458,951 
Non-current restricted cash consists of deposits with financial institutions for corporate credit cards, and such amounts are included in prepaid expenses and other current assets.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
March 31, 2024 December 31, 2023
Prepaid General and Administrative $ 109,395  $ 73,109 
Prepaid Insurance 72,872  123,807 
Prepaid Research and Development 24,404  23,066 
Other —  13,400 
Total Prepaid Expenses and Other Current Assets $ 206,671  $ 233,382 
Accrued Expenses
Accrued expenses consist of the following:
March 31, 2024 December 31, 2023
Payroll and Benefits $ 972,562  $ 875,254 
Professional Fees 57,575  43,387 
Clinical Trials 120,135  397,465 
Other 71,806  64,560 
Total Accrued Expenses $ 1,222,078  $ 1,380,666